Literature DB >> 20214534

Multiple cytokine biomarkers in heart failure.

Maria Vistnes1, Geir Christensen, Torbjørn Omland.   

Abstract

Raised levels of circulating proinflammatory cytokines are associated with disease progression and adverse outcomes in chronic heart failure patients. Inflammatory markers may be predictive of congestive heart failure and myocardial infarction, allowing enhanced risk stratification. The profile of cytokine blood levels differs in accordance with the initiating cause and type of heart failure. Therefore, subclassification of heart failure patients based on cytokine measurements could potentially identify subgroups of patients, permitting tailored or personalized therapy. During inflammatory states, cytokine production is often regulated by activation of other cytokines, resulting in a perpetuating, complex cytokine cascade. Thus, single-assay measurement of cytokines provides limited information, and to obtain a more comprehensive picture of immune activation, multiple cytokines need to be analyzed simultaneously. With the technological development in multiplex protein analyses, multiplexing cytokines has become simple, fast and reproducible. Luminex technology represents one platform for simultaneous measurements of several cytokines, and has gained increasing interest among researchers in recent years. However, the measurement of multiple cytokines as part of a multimarker prognostic or diagnostic biomarker approach remains to be implemented in current clinical practice, as current knowledge of the underlying biology of cytokine release in heart disease is still too limited and a bioinformatic tool for interpretation of cytokine profiles is needed. Nevertheless, multiplex protein analyses are likely to constitute an important part of experimental and clinical research on heart failure and cytokines, paving the way for more accurate heart failure treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20214534     DOI: 10.1586/erm.10.3

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  6 in total

1.  Pentraxin 3 in Circulating Microvesicles: a Potential Biomarker for Acute Heart Failure After Cardiac Surgery with Cardiopulmonary Bypass.

Authors:  Yuan-Kai Song; Hao-Xiang Yuan; Yu-Peng Jian; Ya-Ting Chen; Kai-Feng Liang; Xiao-Jun Liu; Zhi-Jun Ou; Jia-Sheng Liu; Yan Li; Jing-Song Ou
Journal:  J Cardiovasc Transl Res       Date:  2022-07-25       Impact factor: 3.216

2.  Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection.

Authors:  Rebecca Scherzer; Sanjiv J Shah; Eric Secemsky; Javed Butler; Carl Grunfeld; Michael G Shlipak; Priscilla Y Hsue
Journal:  Circ Heart Fail       Date:  2018-04       Impact factor: 8.790

3.  A Modular Cytokine Analysis Method Reveals Novel Associations With Clinical Phenotypes and Identifies Sets of Co-signaling Cytokines Across Influenza Natural Infection Cohorts and Healthy Controls.

Authors:  Liel Cohen; Andrew Fiore-Gartland; Adrienne G Randolph; Angela Panoskaltsis-Mortari; Sook-San Wong; Jacqui Ralston; Timothy Wood; Ruth Seeds; Q Sue Huang; Richard J Webby; Paul G Thomas; Tomer Hertz
Journal:  Front Immunol       Date:  2019-06-18       Impact factor: 7.561

4.  Red cell distribution width predicts short- and long-term outcomes of acute congestive heart failure more effectively than hemoglobin.

Authors:  Yuxiang Dai; Hakuoh Konishi; Atsutoshi Takagi; Katsumi Miyauchi; Hiroyuki Daida
Journal:  Exp Ther Med       Date:  2014-06-04       Impact factor: 2.447

5.  Multiplex Cytokine Profiling of Stimulated Mouse Splenocytes Using a Cytometric Bead-based Immunoassay Platform.

Authors:  Jason S Lehmann; Amy Zhao; Binggang Sun; Weiping Jiang; Shaoquan Ji
Journal:  J Vis Exp       Date:  2017-11-09       Impact factor: 1.355

6.  Dangshen Erling Decoction Ameliorates Myocardial Hypertrophy via Inhibiting Myocardial Inflammation.

Authors:  Yigang Zhong; Liuying Chen; Miaofu Li; Lian Chen; Yufeng Qian; Chaofeng Chen; Yi Wang; Yizhou Xu
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.